Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SinoMab Bioscience Ltd. ( (HK:3681) ) has provided an update.
SinoMab BioScience Limited has announced its 2025 Annual General Meeting scheduled for June 13, 2025. Key agenda items include the re-election of several directors, the re-appointment of Ernst & Young as auditors, and granting the board mandates to buy back shares and issue new shares. These resolutions are aimed at strengthening the company’s governance and providing flexibility in capital management, potentially impacting its market operations and shareholder value.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, focusing on the development and commercialization of therapeutics for the treatment of immunological diseases. The company is engaged in research and development to bring innovative solutions to the market.
YTD Price Performance: 7.34%
Average Trading Volume: 224,950
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.33B
For an in-depth examination of 3681 stock, go to TipRanks’ Stock Analysis page.